ReviewReviews in endocrine & metabolic disorders2011
Update on hormonal contraception and bone density.
Review in Reviews in endocrine & metabolic disorders, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Steroidal contraceptives and bone fractures in women: evidence from observational studies.The Cochrane database of systematic reviews · 2015Pooled it
- TDF and quantitative ultrasound bone quality in African patients on second line ART, ANRS 12169 2LADY sub-study.PloS one · 2017Trial
- Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density.Reproductive sciences (Thousand Oaks, Calif.) · 2014Trial
- Commonly Prescribed and Over-the-Counter Drugs as Secondary Causes of Osteoporosis-Part Two.Integrative medicine (Encinitas, Calif.) · 2021Article
- The clinical relevance of progestogens in hormonal contraception: Present status and future developments.Oncotarget · 2018Review
- Oral contraceptive use and fracture risk-a retrospective study of 12,970 women in the UK.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2017Article
- Contraceptive Considerations for Women with Gastrointestinal Disorders.Digestive diseases and sciences · 2017Review
- Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery.Open access journal of contraception · 2016Review
- Abnormal uterine bleeding: Taking the stress out of controlling the flow.Canadian family physician Medecin de famille canadien · 2015Article
- Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes.Annals of epidemiology · 2015Article
- Bone metabolism in adolescent girls with eating disorders and weight loss: independent effects of weight change, insulin-like growth factor-1 and oestradiol.Eating and weight disorders : EWD · 2015Article
- Postpartum contraception in adolescents: data from a single tertiary clinic in southeast of Turkey.Global journal of health science · 2014Article
- Menstrual suppression: current perspectives.International journal of women's health · 2014Review
- Bone health in children and adolescents with perinatal HIV infection.Journal of the International AIDS Society · 2013Review
- Contraception in women over 40 years of age.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2013Review
- Half a century of the oral contraceptive pill: historical review and view to the future.Canadian family physician Medecin de famille canadien · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combination hormonal contraception and progestin-only contraception (including depot medroxyprogesterone acetate [DMPA]) are effective and convenient forms of reversible contraception that millions of women use worldwide. In recent years, observations of reduced bone mineral density in current users of these methods have led to concerns that this hormone-induced bone loss might translate into long-term increased fracture risk. Special focus has been placed on adolescent users who have not yet attained their peak bone mass as well as perimenopausal users. In 2004, the FDA added a black box warning to DMPA package labeling warning of the risk of significant bone loss and cautioning against long-term use (> 2 years). This article reviews evidence on the use of hormonal contraception and its effect on bone density in adolescent, premenopausal, and perimenopausal populations. Recommendations from reproductive healthcare organizations are reviewed and clinical recommendations are provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.